In one phase 2 study: Pancreatitis was reported in about 0.4% of participants (1 out of 267) Gallbladder issues affected roughly 1.1%, with no cases in the placebo group Heart rhythm changes were reported more often in people taking retatrutide (about 6% compared to 3% with placebo) Liver enzyme increases were rare (around 1%), and overall liver health markers stayed stable over time
Your gut is also home to a huge part of your immune system
Nevzorova 1,3,4 , Affiliation: 1 Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain 3 Centro de Investigacin Biomdica en Red de Enfermedades Hepticas y Digestivas (CIBERehd), 28029 Madrid, Spain 4 Instituto de Investigacin Sanitaria Gregorio Maran (IiSGM), 28007 Madrid, Spain Email: [email protected] ORCID: Francisco Javier Cubero 1,3,4* Abstract The pathogenesis of drug-induced liver injury (DILI) is still in an early stage of research
Why can't retatrutide be compounded when semaglutide was